Home > Research Areas > Cancer > Lung Cancer
Cat. No. Product name CAS No.
DCF-001 Tetrandrine

>98%,Standard References

518-34-3
DC11929 ME-344

A novel mitochondrial and mTOR inhibitor with potent anti-cancer activity, inhibits leukemia cell lines with IC50 of 70-260 nM.

1374524-68-1
DC11721 PF-06747775

A potent, selective, irreversible EGFR mutants with IC50 of 12, 3, 4 and 5 nM for EGFR L858R-T790M, Del-T790M, L858R, and EGFR Del, respectively.

1776112-90-3
DC7353 ABT-751(E 7010) Featured

ABT-751(E 7010) is a novel bioavailable tubulin-binding and antimitotic sulfonamide agent with IC50 of about 1.5 and 3.4 μM in neuroblastoma and non-neuroblastoma cell lines, respectively.

141430-65-1
DC3164 BIBW2992-MA2 (Afatinib dimaleate)

Afatinib is an irreversible EGFR/HER2 inhibitor with an IC50 of 14 nM for in vitro potency against HER2.

850140-73-7
DC8695 Akt1 and Akt2-IN-1

Akt1 and Akt2-IN-1 is an allosteric inhibitor of Akt1 (IC50 = 3.5 nM) and Akt2 (IC50 = 42 nM), with potent and balanced activity.

893422-47-4
DC12072 Alflutinib mesylate (AST2818) Featured

Alflutinib mesylate(AST2818) is an EGFR inhibitor.

2130958-55-1
DC7324 Amuvatinib (MP-470) Featured

Amuvatinib (MP-470) is a potent and multi-targeted inhibitor of c-Kit, PDGFRα and Flt3 with IC50 of 10 nM, 40 nM and 81 nM, respectively.

850879-09-3
DC10009 Avitinib free base Featured

Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity.

1557267-42-1
DC10008 Avitinib maleate Featured

Avitinib is an orally available, irreversible, epidermal growth factor receptor (EGFR) mutant-selective inhibitor, with potential antineoplastic activity.

1557268-88-8
DC8472 AZD-3759 Featured

AZD3759 is an orally available inhibitor of the epidermal growth factor receptor (EGFR), with potential antineoplastic activity.

1626387-80-1
DC1075 AZD4547 Featured

AZD4547 is a novel selective FGFR inhibitor targeting FGFR1, FGFR2, and FGFR3 with IC50 of of 0.2 nM, 2.5 nM, and 1.8 nM, respectively.

1035270-39-3
DC10739 AZD4635 Featured

AZD4635 is a novel adenosine 2A receptor (A2AR) inhibitor with a Ki of 1.7 nM.

1321514-06-0
DC7006 Mereletinib(AZD-9291,Osimertinib) Featured

AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).

1421373-65-0
DC8462 AZD-9291 mesylate (Osimertinib,Mereletinib) Featured

AZD-9291 is a potent and selective mutated forms EGFR inhibitor(Exon 19 deletion EGFR IC50=12.92 nM, L858R/T790M EGFR IC50= 11.44 nM, wild type EGFR IC50= 493.8 nM).

1421373-66-1
DC8280 BLU-9931 Featured

BLU9931 is the first selective small molecule inhibitor of FGFR4 with IC50 of 3 nM; less potent for FGFR1/2/3(IC50> 150 nM).

1538604-68-0
DC3138 Canertinib dihydrochloride Featured

Canertinib dihydrochloride is the hydrochloride salt of an orally bio-available quinazoline with potential antineoplastic and radiosensitizing activities.

289499-45-2
DC7383 CH5424802(Alectinib) Featured

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

1256580-46-7
DC8728 CH5424802(Alectinib HCl) Featured

CH5424802(AF 802; Alectinib) is a potent ALK inhibitor with IC50 of 1.9 nM, sensitive to L1196M mutation.

1256589-74-8
DC7106 Rociletinib (CO-1686) Featured

CO-1686 is a novel, irreversible and orally delivered kinase inhibitor that specifically targets the mutant forms of EGFR including T790M(IC50=21 nM).

1374640-70-6
DC10527 CPI-444 Featured

CPI-444 is an orally administered antagonist of the adenosine A2A receptor. It is designed to block the action of adenosine that is produced by tumors.

1202402-40-1
DC7695 Defactinib (VS-6063, PF-04554878) Featured

Defactinib is a potent, selective, and orally active FAK inhibitor with demonstrated tolerability and preliminary clinical activity working as a single agent as well as in combination with paclitaxel.

1073154-85-4
Page 1 / Total 3 FirstPrevNextLastGoto